159 related articles for article (PubMed ID: 26281674)
1. [Discovery and clinical application of mutations in the cancer genome].
Mano H
Nihon Rinsho; 2015 Aug; 73(8):1251-5. PubMed ID: 26281674
[TBL] [Abstract][Full Text] [Related]
2. [Towards an inventory of oncogenic mutations in cancer].
Theillet C
Bull Cancer; 2010 Nov; 97(11):1223-9. PubMed ID: 21059490
[TBL] [Abstract][Full Text] [Related]
3. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
4. [Kinase inhibitors and their resistance].
Togashi Y; Nishio K
Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
[TBL] [Abstract][Full Text] [Related]
5. [Gene polymorphisms].
Robert J
Bull Cancer; 2010 Nov; 97(11):1253-64. PubMed ID: 21115419
[TBL] [Abstract][Full Text] [Related]
6. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
[TBL] [Abstract][Full Text] [Related]
7. Marked for death: targeting epigenetic changes in cancer.
Pfister SX; Ashworth A
Nat Rev Drug Discov; 2017 Apr; 16(4):241-263. PubMed ID: 28280262
[TBL] [Abstract][Full Text] [Related]
8. Novel tyrosine kinase inhibitors in the treatment of cancer.
Ocana A; Serrano R; Calero R; Pandiella A
Curr Drug Targets; 2009 Jun; 10(6):575-6. PubMed ID: 19519359
[No Abstract] [Full Text] [Related]
9. New targeted therapies for gastric cancer.
Asaoka Y; Ikenoue T; Koike K
Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
[TBL] [Abstract][Full Text] [Related]
10. [New targets and new drugs in thoracic oncology].
Rouviere D; Bousquet E; Pons E; Milia JD; Guibert N; Mazieres J
Rev Mal Respir; 2015 Oct; 32(8):867-76. PubMed ID: 26076869
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of tumor suppressor genes.
Morris LG; Chan TA
Cancer; 2015 May; 121(9):1357-68. PubMed ID: 25557041
[TBL] [Abstract][Full Text] [Related]
12. Targeting epigenetic regulators for cancer therapy.
Wee S; Dhanak D; Li H; Armstrong SA; Copeland RA; Sims R; Baylin SB; Liu XS; Schweizer L
Ann N Y Acad Sci; 2014 Feb; 1309():30-6. PubMed ID: 24571255
[TBL] [Abstract][Full Text] [Related]
13. The immune checkpoint inhibitors: where are we now?
Webster RM
Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
[No Abstract] [Full Text] [Related]
14. Somatic alterations in the human cancer genome.
Weir B; Zhao X; Meyerson M
Cancer Cell; 2004 Nov; 6(5):433-8. PubMed ID: 15542426
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy for NSCLC--A Double-edged Sword?
Dempke WC
Anticancer Res; 2015 May; 35(5):2503-12. PubMed ID: 25964523
[TBL] [Abstract][Full Text] [Related]
16. Mutation Signatures Depend on Epigenomic Contexts.
Coleman N; De S
Trends Cancer; 2018 Oct; 4(10):659-661. PubMed ID: 30292349
[TBL] [Abstract][Full Text] [Related]
17. Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications.
Soussi T; Taschner PE; Samuels Y
Hum Mutat; 2017 Apr; 38(4):339-342. PubMed ID: 28026089
[TBL] [Abstract][Full Text] [Related]
18. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
Workman P
Expert Rev Anticancer Ther; 2002 Dec; 2(6):611-4. PubMed ID: 12503197
[No Abstract] [Full Text] [Related]
19. Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.
Ardini E; Magnaghi P; Orsini P; Galvani A; Menichincheri M
Cancer Lett; 2010 Dec; 299(2):81-94. PubMed ID: 20934803
[TBL] [Abstract][Full Text] [Related]
20. MTOR mutations in the crosshairs of targeted therapy.
Rejto PA; Abraham RT
Cancer Discov; 2014 May; 4(5):513-5. PubMed ID: 24795009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
